300 related articles for article (PubMed ID: 19424576)
1. The expression of Müllerian inhibiting substance/anti-Müllerian hormone type II receptor protein and mRNA in benign, borderline and malignant ovarian neoplasia.
Song JY; Chen KY; Kim SY; Kim MR; Ryu KS; Cha JH; Kang CS; MacLaughlin DT; Kim JH
Int J Oncol; 2009 Jun; 34(6):1583-91. PubMed ID: 19424576
[TBL] [Abstract][Full Text] [Related]
2. Expression of Müllerian-Inhibiting Substance/Anti-Müllerian Hormone Type II Receptor in the Human Theca Cells.
Cheon KY; Chung YJ; Cho HH; Kim MR; Cha JH; Kang CS; Lee JY; Kim JH
J Clin Endocrinol Metab; 2018 Sep; 103(9):3376-3385. PubMed ID: 29947765
[TBL] [Abstract][Full Text] [Related]
3. Anti-müllerian hormone and anti-müllerian hormone type II receptor messenger ribonucleic acid expression in rat ovaries during postnatal development, the estrous cycle, and gonadotropin-induced follicle growth.
Baarends WM; Uilenbroek JT; Kramer P; Hoogerbrugge JW; van Leeuwen EC; Themmen AP; Grootegoed JA
Endocrinology; 1995 Nov; 136(11):4951-62. PubMed ID: 7588229
[TBL] [Abstract][Full Text] [Related]
4. Müllerian inhibiting substance/anti-Müllerian hormone type II receptor protein and mRNA expression in the healthy and cancerous endometria.
Kim SM; Kim YO; Lee MK; Chung YJ; Jeung IC; Kim MR; Kim JH
Oncol Lett; 2019 Jan; 17(1):532-538. PubMed ID: 30655798
[TBL] [Abstract][Full Text] [Related]
5. Anti-Müllerian hormone concentration regulates activin receptor-like kinase-2/3 expression levels with opposing effects on ovarian cancer cell survival.
Chauvin M; Garambois V; Choblet S; Colombo PE; Chentouf M; Gros L; De Brauwere DP; Duonor-Cerutti M; Dumas K; Robert B; Jarlier M; Martineau P; Navarro-Teulon I; Pépin D; Chardès T; Pèlegrin A
Int J Oncol; 2021 Jul; 59(1):. PubMed ID: 34013359
[TBL] [Abstract][Full Text] [Related]
6. Patterns of Müllerian Inhibiting Substance Type II and Candidate Type I Receptors in Epithelial Ovarian Cancer.
Basal E; Ayeni T; Zhang Q; Langstraat C; Donahoe PK; Pepin D; Yin X; Leof E; Cliby W
Curr Mol Med; 2016; 16(3):222-31. PubMed ID: 26917267
[TBL] [Abstract][Full Text] [Related]
7. Assessment of Anti-Mullerian Hormone and Anti-Mullerian Hormone Type II Receptor Variants in Women with Repeated Implantation Failures.
Fu YX; Yang HM; OuYang XE; Hu R; Hu T; Wang FM
Reprod Sci; 2021 Feb; 28(2):406-415. PubMed ID: 32845508
[TBL] [Abstract][Full Text] [Related]
8. Anti-müllerian hormone and anti-müllerian hormone type II receptor messenger ribonucleic acid expression during postnatal testis development and in the adult testis of the rat.
Baarends WM; Hoogerbrugge JW; Post M; Visser JA; De Rooij DG; Parvinen M; Themmen AP; Grootegoed JA
Endocrinology; 1995 Dec; 136(12):5614-22. PubMed ID: 7588316
[TBL] [Abstract][Full Text] [Related]
9. Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS.
Masiakos PT; MacLaughlin DT; Maheswaran S; Teixeira J; Fuller AF; Shah PC; Kehas DJ; Kenneally MK; Dombkowski DM; Ha TU; Preffer FI; Donahoe PK
Clin Cancer Res; 1999 Nov; 5(11):3488-99. PubMed ID: 10589763
[TBL] [Abstract][Full Text] [Related]
10. Anti-Müllerian hormone type II receptor in avian follicle development.
Lemcke RA; Stephens CS; Hildebrandt KA; Johnson PA
Biol Reprod; 2018 Dec; 99(6):1227-1234. PubMed ID: 29931109
[TBL] [Abstract][Full Text] [Related]
11. Placenta expresses anti-Müllerian hormone and its receptor: Sex-related difference in fetal membranes.
Novembri R; Funghi L; Voltolini C; Belmonte G; Vannuccini S; Torricelli M; Petraglia F
Placenta; 2015 Jul; 36(7):731-7. PubMed ID: 25972076
[TBL] [Abstract][Full Text] [Related]
12. Expression of Müllerian inhibiting substance type II receptor and antiproliferative effects of MIS on human cervical cancer.
Song JY; Jo HH; Kim MR; Lew YO; Ryu KS; Cha JH; Kang CS; Donahoe PK; MacLaughlin DT; Kim JH
Int J Oncol; 2012 Jun; 40(6):2013-21. PubMed ID: 22344630
[TBL] [Abstract][Full Text] [Related]
13. Müllerian inhibiting substance, alpha-inhibin, and CD99 expression in sex cord-stromal tumors and endometrioid ovarian carcinomas resembling sex cord-stromal tumors.
Matias-Guiu X; Pons C; Prat J
Hum Pathol; 1998 Aug; 29(8):840-5. PubMed ID: 9712426
[TBL] [Abstract][Full Text] [Related]
14. AAV9 delivering a modified human Mullerian inhibiting substance as a gene therapy in patient-derived xenografts of ovarian cancer.
Pépin D; Sosulski A; Zhang L; Wang D; Vathipadiekal V; Hendren K; Coletti CM; Yu A; Castro CM; Birrer MJ; Gao G; Donahoe PK
Proc Natl Acad Sci U S A; 2015 Aug; 112(32):E4418-27. PubMed ID: 26216943
[TBL] [Abstract][Full Text] [Related]
15. Müllerian inhibiting substance type II receptor (MISIIR): a novel, tissue-specific target expressed by gynecologic cancers.
Bakkum-Gamez JN; Aletti G; Lewis KA; Keeney GL; Thomas BM; Navarro-Teulon I; Cliby WA
Gynecol Oncol; 2008 Jan; 108(1):141-8. PubMed ID: 17988723
[TBL] [Abstract][Full Text] [Related]
16. The expression of Müllerian inhibiting substance/anti-Müllerian hormone type II receptor in myoma and adenomyosis.
Kim SY; Moon HM; Lee MK; Chung YJ; Song JY; Cho HH; Kim MR; Kim JH
Obstet Gynecol Sci; 2018 Jan; 61(1):127-134. PubMed ID: 29372159
[TBL] [Abstract][Full Text] [Related]
17. Anti-Müllerian hormone gene polymorphism is associated with androgen levels in Chinese polycystic ovary syndrome patients with insulin resistance.
Zheng MX; Li Y; Hu R; Wang FM; Zhang XM; Guan B
J Assist Reprod Genet; 2016 Feb; 33(2):199-205. PubMed ID: 26732661
[TBL] [Abstract][Full Text] [Related]
18. Leptin suppresses anti-Mullerian hormone gene expression through the JAK2/STAT3 pathway in luteinized granulosa cells of women undergoing IVF.
Merhi Z; Buyuk E; Berger DS; Zapantis A; Israel DD; Chua S; Jindal S
Hum Reprod; 2013 Jun; 28(6):1661-9. PubMed ID: 23503941
[TBL] [Abstract][Full Text] [Related]
19. The expression of amh and amhr2 is associated with the development of gonadal tissue and sex change in the protandrous black porgy, Acanthopagrus schlegeli.
Wu GC; Chiu PC; Lyu YS; Chang CF
Biol Reprod; 2010 Sep; 83(3):443-53. PubMed ID: 20505169
[TBL] [Abstract][Full Text] [Related]
20. Natural mutations of the anti-Mullerian hormone type II receptor found in persistent Mullerian duct syndrome affect ligand binding, signal transduction and cellular transport.
Belville C; Maréchal JD; Pennetier S; Carmillo P; Masgrau L; Messika-Zeitoun L; Galey J; Machado G; Treton D; Gonzalès J; Picard JY; Josso N; Cate RL; di Clemente N
Hum Mol Genet; 2009 Aug; 18(16):3002-13. PubMed ID: 19457927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
